SUMMARY
Because all nuclei in differentiated, functional myofibers have permanently exited the cell cycle, the satellite
cell population acts as a source of new nuclei when tissue growth, repair, or regeneration is required. Satellite
cells during homeostasis rest in a quiescent, nonproliferative state sandwiched between the cell membrane
and the basal lamina of a differentiated myofiber. In this state they express the satellite stem cell transcription
factor Pax7 but little to no transcription factors of the MyoD family. In response to injury or disease, satellite
cells are activated to re-enter the cell cycle, upregulate MyoD and other myogenic transcription factors, and
expand as myoblasts to generate new myogenic cells, then commit to terminal differentiation and fuse into new
or existing myofibers. Through mechanisms that are not yet well understood a fraction of satellite cell progeny
will re-enter the quiescent state and repopulate the stem cell pool. This process is rapid and highly effective,
and in most cases is sufficient to maintain muscle mass and function throughout life. However, in the case of
muscle degenerative diseases such as Duchenne's muscular dystrophy or massive trauma leading to
volumetric muscle loss, endogenous satellite cells are insufficient or unable to repair the muscle leading to
long-term pathology. A longstanding goal in the field has been isolating patient- or donor-derived satellite cells
and expanding them ex vivo (potentially in concert with manipulations such as repair of the dystrophin gene)
then engrafting them therapeutically, however this approach has not yet met with good success. One major
hurdle is the difficulty of maintaining satellite cells and their progeny in a proliferative progenitor state in vitro:
they tend to commit to terminal differentiation even under high-mitogen conditions, and even those cells that
remain proliferative largely lose their stem cell character (e.g., ability to self-renew as satellite cells in vivo). We
have exciting new data showing that in the absence of the cell surface signaling molecule ephrin-A5,
myoblasts will not only not commit to terminal differentiation but they will, when grown at high densities, instead
exit the cell cycle and express high levels of Pax7, thus resembling quiescent satellite cells in at least two key
respects. When repassaged at low density, these cells will re-enter the cell cycle and expand again without
committing to terminal differentiation. To leverage this result into a potential translational application, we
propose to attempt to transiently and reversibly inhibit (rather than delete) ephrin-A5, to allow myoblast
expansion in culture without loss to differentiation and ideally to enhance stem cell character on engraftment.
We have chosen to develop RNA aptamers as ephrin-A5 inhibitors in order to take advantage of aptamers'
high specificity of binding, absence of immunogenicity, potential for additional chemical functionalization, and
speed and cost-effectiveness to generate. If successful, this technique has the potential to significantly
advance cell-based therapies for DMD and volumetric muscle loss and to accelerate basic science by allowing
researchers to generate of large numbers of progenitor cells over extended culture periods.